India set for new study on spurious drugs
This article was originally published in SRA
Executive Summary
India is continuing its efforts to improve its regulatory oversight in the pharmaceutical segment. The country has now initiated steps for a new study on spurious drugs and plans to expand the number of adverse drug reactions (ADR) monitoring centres in the country.